Ganoderma lucidum inhibits proliferation of human ovarian cancer cells by suppressing VEGF expression and up-regulating the expression of connexin 43 by Shuyan Dai et al.
Dai et al. BMC Complementary and Alternative Medicine 2014, 14:434
http://www.biomedcentral.com/1472-6882/14/434RESEARCH ARTICLE Open AccessGanoderma lucidum inhibits proliferation of
human ovarian cancer cells by suppressing VEGF
expression and up-regulating the expression of
connexin 43
Shuyan Dai*, Jingjing Liu, Xiaofei Sun and Ning WangAbstract
Background: Ganoderma lucidum (G. lucidum, Reishimax) is an herbal mushroom known to have inhibitory effect
on tumor cell growth. However, the molecular mechanisms responsible for its anti-proliferative effects on the
ovarian cancer have not been fully elucidated.
Methods: Human ovarian cancer cells HO 8910 (HOCC) and human primary ovarian cells (HPOC) were treated
with G. lucidum. Effects of G. lucidum treatment on cell proliferation were studied by MTT assay. The expression of
vascular endothelial growth factor (VEGF) and connexin 43 (Cx43) were measured by immunohistochemistry and
real time polymerase chain reaction. To study the molecular mechanism of CX43 mediated anti-tumor activity,
small interference RNA (siRNA) was used to knockdown Cx43 expression in HOCC.
Results: G. lucidum treatment resulted in reduced proliferation of HOCC. Inhibition of proliferation was accompanied
by a decrease in VEGF expression and increase in Cx43 expression in the cancer cells. The extent of immune-reactivity
of Cx43 or VEGF in cancer cells were correlated with the concentrations of G. lucidum used for treatment. Furthermore,
knockdown of Cx43 expression in HOCC abrogated the effect of G. lucidum on cell proliferation without alteration of
G. lucidum-induced attenuation of VEGF expression.
Conclusions: G. lucidum inhibits ovarian cancer by down-regulating the expression of VEGF and up-regulating the
downstream Cx43 expression. G. lucidum may be a promising therapeutic agent for the treatment of ovarian cancer.
Keywords: Ganoderma lucidum, Ovarian cancer, Real-time PCR, Immunohistochemistry, Vascular endothelial growth
factor (VEGF), Connexin 43 (Cx43)Background
Ovarian cancer is the most frequent cause of cancer
related death in women [1]. The high mortality can be
attributed to late diagnosis and lack of effective treat-
ment especially at later stages of the disease. Dried pow-
der of a medicinal mushroom Ganoderma lucidum has
been used in Chinese traditional medicine for over two
thousand years. The mushroom is also used as a dietary
supplement in other parts of the world. Extracts of the* Correspondence: daishy2014@163.com
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unless otherwise stated.mushroom are known to have several biological proper-
ties including anti-tumor activities on different cancer
cells lines.
The anti-cancer activity of G. lucidum is observed at
different stages of carcinogenesis. Anti-cancer activity of
the mushroom includes cell cycle arrest, induction of
apoptosis and autophagy, and suppression of metastasis
and angiogenesis [2]. G. lucidum has been shown to
exert multiple anti-tumor effects on ovarian cancer
cells and enhance the sensitivity of epithelial ovarian
cancer (EOC) cells to cisplatin [3,4]. However, the mo-
lecular mechanism responsible for the inhibitory effects
of G. lucidum on the ovarian cancer has not been fully
elucidated.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Dai et al. BMC Complementary and Alternative Medicine 2014, 14:434 Page 2 of 8
http://www.biomedcentral.com/1472-6882/14/434Vascular endothelial growth factor (VEGF) is an im-
portant regulator of vascular endothelial cell functions
during tumor growth. Ovarian cancer cells secrete large
amounts of VEGF, which plays a crucial role in the
accumulation of ascites fluid, angiogenesis and tumor
induced immunosuppression in ovarian cancer patients
[5]. Increased expression of VEGF is also associated with
poor prognosis in ovarian cancer patients [6,7]. Gap
junction is an important cell to cell communication
structure playing an important role in physiological
functions like cell differentiation, cell growth and tissue
homeostasis. Several second messengers, small metabo-
lites, and peptides for basic cell physiological activities
are transported through the gap junctions [8]. Several
carcinogens were shown to decrease the expression of
connexins [9], while enhancement of connexin function
had an inhibitory effect on the growth of cancers [10,11].
The gap junction gene connexin 43 (Cx43) shows tumor-
suppressing effects on various tumors [12]. Decrease in
the expression of Cx43 was shown to decrease the sensi-
tivity of ovarian cancer cells to chemotherapeutic agents.
However the molecular mechanism of Cx43 on suppres-
sion of ovarian cancer is not known yet. Some studies have
indicated that human ovarian surface epithelial cells and
surgical specimens of normal ovary exhibit extensive Cx43
expression, whereas Cx43 expression in ovarian adenocar-
cinomas is nearly absent. These findings suggest that the
loss of gap junctions and Cx43 are associated with a neo-
plastic process [13,14]. Loss of gap junctional intercellular
communication (GJIC) is critical for tumor progression
because it allows the cells to escape growth control [15]. A
defect in posttranslational phosphorylation of Cx43 pro-
tein is associated with low expression of the Cx43 gene
which may be responsible for the GJIC deficiency in AB1
cells. Increased expression of Cx43 by gene amplification
may restore this phosphorylated Cx43 protein and rees-
tablish GJIC [16]. It has been reported that VEGF can
stimulate the expression of Cx43 in cardiac myocytes
[17,18]. G. lucidum extracts are known to inhibit the
expression of VEGF in a variety of cancer cell lines but its
effect on Cx43 is not known. In the present study, we
tested the effect of G. lucidum on amelioration of ovarian




Cell culture reagents were purchased from Invitrogen
(Carlsbad, CA). G. lucidum (Reishimax) was purchased
from Pharmanex Guoyao Co. (Wuhan, China). This
product was a standard extract of G lucidum, containing
6% triterpenes and 13.5% polysaccharides. The same prod-
uct has been demonstrated to suppress growth of breast
cancer cells [19], prevent breast-to-lung cancer metastasis[20], inhibit adipocyte differentiation, stimulate glucose
uptake and activate AMPK [21]. Stock solution was
prepared by dissolving the sample in sterile water at
a concentration of 50 mg/ml and stored at 4°C, as
described earlier [19].
Cell culture
Human ovarian cancer cells HO 8910 (HOCC) were
purchased from Shanghai Bluegene Biotech CO., LTD
(Shanghai, China). Human primary ovarian cells (HPOC)
were purchased from the Institute of Biochemistry and
Cell Biology (Shanghai, China). All cells were cultured in
RPMI 1640 supplemented with 10% fetal bovine serum,
penicillin (100 IU/ml), and streptomycin (100 μg/ml).
HOCC and HPOC proliferation assay
HOCC and HPOC were harvested using 0.05% trypsin.
Cells were suspended (40,000 cells/ml) in DMEM with
20% FBS, plated onto gelatinized 96-well culture plates
(0.1 ml/well), and incubated at 37°C and 5% CO2 for
24 hours. The media was replaced with 0.1 ml of DMEM
and 5% FBS with or without the addition of 10 ug/ml
G. lucidum and incubated for 24, 48 and 72 h, at 37°C, 5%
CO2. Cell proliferation was determined using MTT assay,
mRNA expression and protein levels for Cx43 and VEGF
were measured by real time PCR and Western blotting.
Small interference RNA (siRNA) transfection
Cx43 siRNA and scrambled siRNA siRNA were designed
and synthesized by Wuhan Genesil Biotechnology Co
(Wuhan, China). The sequences for siRNAs were as
follows: Cx43 siRNA: GCTGGTTACTGGCGACAGA;
scrambled siRNA: TTCTCCGAACGTGTCACGT [22].
HOCC cells (40,000 cells/ml) in DMEM with 20% FBS,
were plated on gelatinized 96-well culture plates (0.1 ml/
well), and incubated at 37°C and 5% CO2 for 24 h. The
media was replaced with 0.1 ml of DMEM and 5% FBS
with the addition of 10 ug/mlG. lucidum. Cx43 siRNA
(40 nmol/L) or scrambled siRNA was transfected into
the cells using Lipofectamine 2000 reagent (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. The dose of Cx43 siRNA was selected
based on a previous study which resulted in maximal
knockdown of Cx43 expression in human aortic endo-
thelial cells [22]. HOCC cells treated with 10 ug/ml
G. lucidum alone served as control. After 72 h incuba-
tion at 37°C and 5% CO2, Cell proliferation was deter-
mined using MTT assay, mRNA expression and protein
levels for Cx43 and VEGF were measured with real time
PCR and Western blotting.
Real time PCR
Real time PCR was performed using a Stratagene Mx3005P®
QPCR System instrument (La Jolla, CA, USA) according to
Figure 1 Growth curve of HOCC and HPOC in DMEM with 5%
BCS or with addition of 10 ug/mlG. lucidum. Proliferation ratio
(%) indicates the cell proliferation rate at other times compared with
that at 0 h when cell numbers are considered as 100%. n = 5, Data
are shown as mean ± S.D. *P < 0.05 vs HOCC + G. lucidum.
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and HPOC, followed by cDNA synthesis and data ana-
lysis as described previously [23]. Primers used for the
real time qPCR were as following: Cx43, 5′-GGGTGA
CTGGAGCGCCTTAG-3′and 5′-TTATCTCAATCTGC
TTCAAG-3′. VEGF, 4, 5′-AAGGAAGAGG AGAGGG
GGCC-3′ and 5′- CTCCTCCTTCTGCCATGGGTG -3′;
GAPDH, 5′-CCCTTCATTGACCTCAACTAC-3′ and 5′-
CCACCTTCTTGATGTCATCAT-3′. GAPDH was used
as an internal control.
Western blotting
HOCC and HPOC cells were homogenized in RIPA buf-
fer (150 mM Sodium chloride, 1% NP-40, 0.5% sodium
deoxycholate, 0.1% SDS, 50 mM Tris-HCl (pH 8.0) con-
taining protease inhibitor (Complete Mini Roche). After
centrifugation the supernatants were boiled and mixed
with an equal volume of sample buffer. Proteins were
separated by SDS–PAGE and transferred to a polyvinyli-
dene difluoride membrane (Millipore). The membranes
were blocked with 5% skim milk in TBST (10 mM Tris
(pH 7.5), 100 mM NaCl and 0.1% Tween 20) and incu-
bated with primary antibodies 1 in TBST with 0.5% skim
milk overnight at 4°C. The membrane was treated with
primary antibodies and horseradish peroxidase-conjugated
goat anti-mouse immunoglobulin G antibody (1:3000)
(Amersham Biosciences) as secondary antibody. Immuno-
reactive bands were visualized by ECL (GE Healthcare)
and quantified by densitometry with Image J software 1.45
(NIH, Bethesda, USA).
Immunohistochemistry
Goat anti-mouse VEGF antibody (R&D Systems Inc.
Minneapolis, MN. USA) and the goat anti-Cx43 anti-
body (Santa Cruz Biotechnology Inc., Santa Cruz, CA,
USA) were used for immunohistochemical staining for
VEGF AND Cx43. The HOCC and HPOC were fixed and
processed in 10 mM of sodium citrate buffer (pH 7.6) in a
microwave oven for four min twice at 70% power.
Endogenous peroxidase was blocked by 5% hydrogen
peroxide for 5 min. Nonspecific binding sites were
blocked by 2% normal horse serum for 20 min. The
samples were incubated with the primary antibodies
for 60 min. Immunoreactivity was visualized by using
DAKO Envision HRP System (1:10,000 dilution) (DAKO,
Carpinteria, California, USA). Immunoreactivity was quan-
titatively evaluated using NIH image program. A score of
0–300 was calculated as the product of the intensity score
and the percent of immunoreactivity.
Statistical analysis
The association between the levels of immunoreactivity
of Cx43 or VEGF and the concentration of G. lucidum
was compared by one-way analysis of variance (ANOVA).The post hoc test used was Fisher’s protected least sig-
nificant difference (LSD) test. Spearman's rank correl-
ation coefficient was used to identify the strength of
correlation between the levels of the Cx43 or VEGF and
the concentration of G. lucidum. Data was analyzed using
Statview 5.0 software (Abacus systems, Berkley CA) with a
p value of <0.05 accepted as significant.
Results
HOCC and HPOC growth curve
The HOCC and HPOC were cultured in DMEM with 1
5% FBS for 24, 48 and 72 h. The results for cell prolifer-
ation are shown in Figure 1. G. lucidum inhibited the
growth of HPOC by less than 10% while it inhibited the
growth of HOCC by up to 60% after 3 days of culture.
These results suggest that G. lucidum effectively pre-
vents the cell proliferation in HOCC.
G. lucidum increases Cx43 mRNA expression and reduces
VEGF mRNA expression
The expression of Cx43 mRNA increased after 3 days of
culture (P <0.05) in both untreated and G. lucidum-
treated groups, compared with day 0 in HPOC cells
(Figure 2). The VEGF mRNA expression in untreated
group remained constant during 3 days of culture. How-
ever, VEGF mRNA expression in G.lucidum-treated group
was found to be significantly reduced on day 3 in the
HPOC cells. The expression of Cx43 mRNA decreased in
the untreated group at day 2 and day 3 in HOCC cells.
In contrast, the Cx43 mRNA expression in G. lucidum-
treated group significantly increased from day 1 and
remained at a high level on day 3. The VEGF mRNA
expression in untreated group significantly increased by
day 2 and continued to increase on day 3. However, no
significant change in VEGF mRNA expression was
observed in G. lucidum-treated group during the 3 days
Figure 2 The relative levels of Cx43 and VEGF mRNA in HOCC and HPOC. “-” stands for untreated group (control). “+” stands for
G. lucidum-treated group at dose of 10 ug/ml. Data are shown as mean ± S.D. of three independent experiments. All the cells were treated
with G. lucidum for successive 3 days. *P < 0.05 vs respective day 0; †P < 0.05 vs corresponding untreated group.
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effectively increases Cx43 mRNA expression and inhibits
VEGF mRNA expression in HOCC but not in HPCC.
G. lucidum increases Cx43 protein expression and
decreases VEGF protein expression
In untreated groups, the expression of Cx43 protein
increased in HPOC, whereas it decreased in HOCC
during 3 days of culture (Figures 3 and 4). The VEGF
protein expression increased in both HPOC and HOCC
at day 3. In treated group, the Cx43 protein expression
was significantly augmented in both HPOC and HOCC
at day 3. The increase in Cx43 protein expression was
more pronounced in HOCC compared with HPOC. As
expected, the VEGF protein expression was efficiently
suppressed in both HOCC and HPOC treated with G
lucidum. Thus, these results are consistent with mRNA
data from our study and other report in the ovarian
cancer cell [14], suggesting that HOCC are sensitive to
G. lucidum treatment.Figure 3 Representative Western blots for Cx43 and VEGF in HOCC anThe effects of G. lucidum on the protein levels of Cx43
and VEGF in a dose-dependent way in HOCC
In HPOC, increase in G. lucidum concentration did not
induce significant changes in protein level of Cx43 or
VEGF (Figure 5). In contrast, increase in G. lucidum
concentration increased protein level of Cx43 and de-
creased protein level of VEGF in a dose dependent man-
ner in HOCC. Furthermore, Spearman’s rank correlation
coefficient showed a significant correlation between the
concentration of G. lucidum and protein level of Cx43
or VEGF in HOCC but not in HPOC (Figure 6).
Knockdown of Cx43 abrogates the effect of G. lucidum on
HOCC proliferation without alteration of G. lucidum-induced
attenuation of VEGF
To further explore the molecular mechanism involved in
the down-regulation of VEGF expression and up-regulation
of Cx43 expression by G. lucidum, we examined the effects
of knockdown of Cx43 on VEGF expression and cell prolif-
eration in HOCC treated with G. lucidum. As shown ind HPOC treated with or without G. lucidum.
Figure 4 Quantitative comparison of protein levels for Cx43 and VEGF in HOCC and HPOC treated with or without G. lucidum. Data are
shown as mean ± S.D. of three independent experiments. *P < 0.05 vs respective day 0; †P < 0.05 vs corresponding untreated group.
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expression and protein levels for Cx43 and VEGF (Figure 7),
and cell proliferation (Figure 8) at day 0. G. lucidum
treatment significantly increased Cx43 expression, and
prevented the expression of VEGF and cell proliferation
in control group at day 3. Cx43 siRNA, but not scram-
bled siRNA, markedly reduced Cx43 expression at day 3
in HOCC treated with G. lucidum. Reduction in Cx43
expression by Cx43 siRNA did not alter G. lucidum-
induced attenuation of VEGF, but abrogated the benefi-
cial effects of G. lucidum on cell proliferation.
Discussion
Ovarian cancer is the most frequent cause of gyneco-
logic cancer-related death in women [24]. Clinical and
pathological diagnosis carried out by various scans andFigure 5 Dose-dependent effects of G. lucidum on Cx43 (A and C) or V
control (0 μg/ml).tumor biopsies are key factors for correct and timely
treatment [25-27]. Few cancer biomarkers are also cur-
rently used for population screening, disease diagnosis,
prognosis, monitoring of therapy and prediction of
therapeutic response [28].
The anticancer effects of G. lucidum have been attributed
to its bioactive compounds including polysaccharides and a
group of triterpenes [3]. The precise molecular mechanism
by which G. lucidum exerts its anticancer properties
on ovarian cancer remains incompletely understood.
Our present study suggests that G. lucidum treatment
reduced the expression of VEGF and increased the
expression of Cx43, in a dose dependent manner,
which was accompanied by decreased cell proliferation
in HOCC. More importantly, we found that knock-
down of Cx43 with siRNA abrogated the beneficialEGF (B and D) protein levels in HOCC and HPOC. *P < 0.05 vs
Figure 6 The relationship between the different concentrations of G. lucidum and Cx43 (A and C) or VEGF (B and D) protein levels in
HOCC and HPOC. Statistical analysis was done by Spearman’s rank correlation test.
Figure 7 Effects of Cx43 siRNA or scrambled siRNA on mRNA and protein levels of Cx43 (A and C) and VEGF (B and D) in HOCC treated
with G. lucidum.
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Figure 8 Effects of Cx43 siRNA or scrambled siRNA on cell
proliferation in HOCC treated with G. lucidum. Cells were
collected before (day 0) and 3 days after co-treatment with G. lucidum
and siRNAs. Data are shown as mean ± S.D. of three independent
experiments. *P < 0.05 vs respective day 0; †P < 0.05 vs corresponding
control or scrambled group.
Dai et al. BMC Complementary and Alternative Medicine 2014, 14:434 Page 7 of 8
http://www.biomedcentral.com/1472-6882/14/434effect of G. lucidum on cell proliferation without alter-
ing the G. lucidum-induced attenuation of VEGF in
HOCC. These findings suggest that VEGF acts down-
stream Cx43 to mediate cell proliferation. G. lucidum
exhibits an anticancer effect by up-regulating Cx43
expression via down-regulation of VEGF expression.
Previous studies showed that VEGF increased the pro-
tein expression of Cx43 in endothelial cells and cardiac
myocytes [17,18]. The discrepancy between our results
and others might be due to differences in cell type and
treatment method.
Our results indicate that CX43 and VEGF play im-
portant roles in the genesis and development of ovar-
ian cancer. Measurements of CX43 and VEGF may
also be useful in evaluating effects of treatment. Cx43
is one of the major gap junction proteins which are im-
portant for intercellular communication, cell homeo-
stasis and proliferation [29]. VEGF may be a useful
serological biomarker for clinical diagnosis and prog-
nosis of ovarian cancer, follow-up of ovarian tumor
metastasis and for monitoring the efficacy of therapy
in patients with ovarian carcinomas [30]. Thus, the
combination of Cx43 and VEGF may provide better
diagnosis of ovarian cancer. It is known that healthy
subjects have higher expression of Cx43 than patients
with ovarian cancer. Our data suggests that Cx43 im-
munological activity could be used as an ancillary
study in the cases that are clinically suspicious for pri-
mary ovarian malignancy.
A major limitation of the present study should be ac-
knowledged. The effect of G. lucidum on cell prolifera-
tion in HOCC was compared with untreated HOCC and
HPOC. However, HPOC cells did not proliferate with
the same intensity as HOCC cells. Nevertheless, thedecreased cell proliferation was clearly observed in G.
lucidum-treated HOCC, indicating anticancer action of
G. lucidum in ovarian cancer.
Conclusions
In conclusion, the present study demonstrates that
G. lucidum inhibits ovarian cancer by down-regulating the
expression of VEGF and up-regulating the downstream
Cx43 expression. G. lucidum may be a promising thera-
peutic agent for the treatment of human ovarian cancer.
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